Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07646860 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Lead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLC Start date changed from estimate of Sep 25, 2026 to Sep 17, 2026 · Eligibility criteria expanded, about 18 words · Secondary endpoints: details revised at 8 of 13 entries · 1 more Show 4 more changesShow less
    • Start date changed from estimate of Sep 25, 2026 to Sep 17, 2026
    • Eligibility criteria expanded, about 18 words
    • Secondary endpoints: details revised at 8 of 13 entries
    • Site details revised at 1 of 3 sites
  2. Study sites: 1 to 3 Start date: Aug 31, 2026 to Sep 25, 2026v3 Show 1 more changeShow less
    • Start date: Aug 31, 2026 to Sep 25, 2026
  3. Recruitment opened Study sites: 0 to 1v2 Show 1 more changeShow less
    • Study sites: 0 to 1
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Merck (MSD)
407 trials monitored
See 29 trials at risk
Hypertension
1,795 trials monitored
See 85 trials at risk
The goal of this study is to learn about the safety of sotatercept and how well Japanese children tolerate it, when taken along with standard (usual) pulmonary arterial hypertension (PAH) treatment. Researchers also want to learn what happens to it in a person's body over time and whether it lowers resistance in blood vessels in the lungs.
Trial Details
NCT Number NCT07646860
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Pulmonary Arterial Hypertension
Enrollment 6 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov